Search Results: Treatment + Ovarian Cancer (10 results)
Study of a New Treatment Called TNG348 in People with Advanced or Metastatic Cancer and with a BRCA1 or BRCA2 Mutation or HRD Positive Tumor
https://www.facingourrisk.org/research-clinical-trials/study/296/study-of-a-new-treatment-called-tng348-in-people-with-advanced-or-metastatic-cancer-and-with-a-brca1-or-brca2-mutation-or-hrd-positive-tumor
Treatment
Treatment for patients who have advanced breast, ovarian, pancreatic, and prostate cancer and a BRCA1 or BRCA2 mutation or have an HRD positive tumor
The study will test the safety and effectiveness of a new drug called TNG348 used alone or in combination with Olaparib (a PARP inhibitor.) The study is for patients who have advanced breast, ovarian, pancreatic, and prostate cancer and a BRCA1 or BRCA2 mutation or have an HRD positive tumor.
Study of a New Immunotherapy Treatment Called NC410 in People with Different Types of Advanced or Metastatic Cancers
https://www.facingourrisk.org/research-clinical-trials/study/251/study-of-an-immunotherapy-treatment-in-individuals-with-advanced-or-metastatic-solid-tumors
Treatment
People with advanced or metastatic colorectal, endometrial, ovarian, stomach, esophageal or other cancers
This study will test the safety and effectiveness of using a new immunotherapy drug called NC410 to treat people with different types of metastatic or advanced cancers.
Combining the Immunotherapy Dostarlimab and PARP Inhibitor Niraparib for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with an Inherited or Tumor BRCA Mutation
https://www.facingourrisk.org/research-clinical-trials/study/231/immunotherapy-and-parp-inhibitor-for-advanced-or-metastatic-breast-ovarian-or-pancreatic-cancer-with-a-brca-mutation
Treatment
Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation
This study is looking at the effectiveness of combining a PARP inhibitor called niraparib and an immunotherapy called dostarlimab for treating people with an inherited BRCA mutation (found with genetic testing) or a tumor mutation (found through tumor testing) who have breast, pancreatic, ovarian, fallopian tube or primary peritoneal cancer that is metastatic or advanced and cannot be removed by surgery (unresectable).
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer
https://www.facingourrisk.org/research-clinical-trials/study/262/tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer
Treatment
Cancer treatment study for people with advanced solid tumors
The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.
Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib
https://www.facingourrisk.org/research-clinical-trials/study/230/treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib
Treatment
Treatment study for people with advanced solid tumors
This study is looking whether the drug Talazoparib (also known as Talzenna) is safe and effective for treating people with advanced solid cancers (including breast, gastric, ovarian, pancreatic, prostate or other solid tumors) in people with an inherited mutation (found through genetic testing) or an acquired mutation (found with biomarker testing) in ATM, ATR, BRCA1, BRCA2, BRIP1, BAP1, BARD1, CDK12, CHEK1, CHEK2, IDH1, IDH2, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or other genes.
Combination ATR inhibitor and PARP Inhibitor in Recurrent Ovarian Cancer (CAPRI)
https://www.facingourrisk.org/research-clinical-trials/study/156/combination-atr-inhibitor-and-parp-inhibitor-in-recurrent-ovarian-cancer-capri
Treatment
Recurrent ovarian cancer
This study will look at how well patients with recurrent ovarian, primary peritoneal or fallopian tube cancer respond to treatment with a targeted therapy known as an ATR inhibitor when combined with the PARP inhibitor Olaparib.
NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/204/nuv-868-alone-and-in-combination-with-parp-inhibitors-in-patients-with-advanced-solid-tumors
Treatment
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer
This study will test how safe and effective the experimental drug NUV-868 is by itself and in combination with a PARP inhibitor in people with advanced solid tumors. The first part of the study will include people with any solid tumor type, and the second part will include people with triple-negative breast, ovarian, pancreatic or prostate cancers only.
Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)
https://www.facingourrisk.org/research-clinical-trials/study/176/investigational-parp-inhibitor-azd5305-alone-or-combined-with-other-anti-cancer-agents-in-people-with-advanced-solid-tumors-petra
Treatment
Advanced ovarian, breast, prostate or pancreatic cancer
PETRA is studying a new PARP inhibitor AZD5305 taken either alone or combined with other treatments in people with advanced ovarian, breast, prostate or pancreatic cancer with an inherited or tumor mutation in: BRCA1/2, PALB2, RAD51C or RAD51D. The treaments participants receive will depend on their cancer type, mutation and when they join the study.
Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/157/treatment-with-atr-inhibitor-for-advanced-or-metastatic-solid-tumors
Treatment
Advanced solid tumors
This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes linked to DNA damage repair. The study will look at response to treatment with the drug ART0380 in combination with the chemotherapy agent, gemcitabine.
A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate and Pancreatic Cancer Patients
https://www.facingourrisk.org/research-clinical-trials/study/102/a-randomized-study-of-an-ehealth-delivery-alternative-for-cancer-genetic-testing-for-hereditary-predisposition-in-metastatic-breast-ovarian-prostate-and-pancreatic-cancer-patients-e-reach
Treatment
Genetic testing can be helpful to identify potential targeted treatments for some patients with metastatic cancer. But some patients have a hard time getting easy and fast testing. This study is looking at using web options to increase access to testing AND patients in this study can get genetic counseling and testing in their home! For more information visit the E-Reach registration page.
Additional Results on Clinicaltrials.gov Treatment + Ovarian Cancer
173 results
huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer
NCT ID: NCT05057715 (https://classic.clinicaltrials.gov/show/NCT05057715)
NeoVax With Nivolumab in Patients With Ovarian Cancer
NCT ID: NCT04024878 (https://classic.clinicaltrials.gov/show/NCT04024878)
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
NCT ID: NCT05568680 (https://classic.clinicaltrials.gov/show/NCT05568680)
Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Ovarian Cancer
NCT ID: NCT05271318 (https://classic.clinicaltrials.gov/show/NCT05271318)
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT ID: NCT03907527 (https://classic.clinicaltrials.gov/show/NCT03907527)
Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer
NCT ID: NCT05225363 (https://classic.clinicaltrials.gov/show/NCT05225363)
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT ID: NCT03026062 (https://classic.clinicaltrials.gov/show/NCT03026062)
Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients
NCT ID: NCT05114421 (https://classic.clinicaltrials.gov/show/NCT05114421)
Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT ID: NCT04387227 (https://classic.clinicaltrials.gov/show/NCT04387227)
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
NCT ID: NCT05231122 (https://classic.clinicaltrials.gov/show/NCT05231122)
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
NCT ID: NCT02264678 (https://classic.clinicaltrials.gov/show/NCT02264678)
CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
NCT ID: NCT05942300 (https://classic.clinicaltrials.gov/show/NCT05942300)
Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
NCT ID: NCT05756907 (https://classic.clinicaltrials.gov/show/NCT05756907)
Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer
NCT ID: NCT02672098 (https://classic.clinicaltrials.gov/show/NCT02672098)
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
NCT ID: NCT04673448 (https://classic.clinicaltrials.gov/show/NCT04673448)
Phase I/IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors
NCT ID: NCT05797168 (https://classic.clinicaltrials.gov/show/NCT05797168)
A Study of FRaDCs for Ovarian Cancer
NCT ID: NCT05920798 (https://classic.clinicaltrials.gov/show/NCT05920798)
Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors
NCT ID: NCT06276491 (https://classic.clinicaltrials.gov/show/NCT06276491)
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
NCT ID: NCT04919629 (https://classic.clinicaltrials.gov/show/NCT04919629)
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Primary Cytoreductive Surgery
NCT ID: NCT06290193 (https://classic.clinicaltrials.gov/show/NCT06290193)
HIPEC After Initial CRS in Patients Who Have Received NACT
NCT ID: NCT03540017 (https://classic.clinicaltrials.gov/show/NCT03540017)
MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
NCT ID: NCT02068794 (https://classic.clinicaltrials.gov/show/NCT02068794)
Identifying and Caring for Individuals With Inherited Cancer Syndrome
NCT ID: NCT04494945 (https://classic.clinicaltrials.gov/show/NCT04494945)
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
NCT ID: NCT05617755 (https://classic.clinicaltrials.gov/show/NCT05617755)
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
NCT ID: NCT03428802 (https://classic.clinicaltrials.gov/show/NCT03428802)
Prehabilitation for Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
NCT ID: NCT05047926 (https://classic.clinicaltrials.gov/show/NCT05047926)
Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency
NCT ID: NCT06120972 (https://classic.clinicaltrials.gov/show/NCT06120972)
A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer
NCT ID: NCT03574779 (https://classic.clinicaltrials.gov/show/NCT03574779)
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
NCT ID: NCT06090266 (https://classic.clinicaltrials.gov/show/NCT06090266)
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
NCT ID: NCT05039801 (https://classic.clinicaltrials.gov/show/NCT05039801)
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
NCT ID: NCT05226507 (https://classic.clinicaltrials.gov/show/NCT05226507)
T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors
NCT ID: NCT05200559 (https://classic.clinicaltrials.gov/show/NCT05200559)
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
NCT ID: NCT05071937 (https://classic.clinicaltrials.gov/show/NCT05071937)
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT ID: NCT04644068 (https://classic.clinicaltrials.gov/show/NCT04644068)
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
NCT ID: NCT04633239 (https://classic.clinicaltrials.gov/show/NCT04633239)
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Platinum-doublet + Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076)
NCT ID: NCT05281471 (https://classic.clinicaltrials.gov/show/NCT05281471)
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
NCT ID: NCT04315233 (https://classic.clinicaltrials.gov/show/NCT04315233)
ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
NCT ID: NCT03287271 (https://classic.clinicaltrials.gov/show/NCT03287271)
Combination Therapy for Recurrent Ovarian Cancer
NCT ID: NCT05610735 (https://classic.clinicaltrials.gov/show/NCT05610735)
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
NCT ID: NCT03734692 (https://classic.clinicaltrials.gov/show/NCT03734692)
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
NCT ID: NCT05983276 (https://classic.clinicaltrials.gov/show/NCT05983276)
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
NCT ID: NCT05092373 (https://classic.clinicaltrials.gov/show/NCT05092373)
Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
NCT ID: NCT03321188 (https://classic.clinicaltrials.gov/show/NCT03321188)
Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
NCT ID: NCT05467670 (https://classic.clinicaltrials.gov/show/NCT05467670)
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
NCT ID: NCT05636111 (https://classic.clinicaltrials.gov/show/NCT05636111)
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT ID: NCT06242470 (https://classic.clinicaltrials.gov/show/NCT06242470)
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
NCT ID: NCT06083844 (https://classic.clinicaltrials.gov/show/NCT06083844)
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT ID: NCT03579316 (https://classic.clinicaltrials.gov/show/NCT03579316)
GEN1047 for Solid Tumors - First in Human (FIH) Trial
NCT ID: NCT05180474 (https://classic.clinicaltrials.gov/show/NCT05180474)
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
NCT ID: NCT05113368 (https://classic.clinicaltrials.gov/show/NCT05113368)
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT ID: NCT02830724 (https://classic.clinicaltrials.gov/show/NCT02830724)
Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
NCT ID: NCT03564340 (https://classic.clinicaltrials.gov/show/NCT03564340)
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
NCT ID: NCT03772028 (https://classic.clinicaltrials.gov/show/NCT03772028)
Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian
NCT ID: NCT04670068 (https://classic.clinicaltrials.gov/show/NCT04670068)
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
NCT ID: NCT05092360 (https://classic.clinicaltrials.gov/show/NCT05092360)
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT ID: NCT04251052 (https://classic.clinicaltrials.gov/show/NCT04251052)
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
NCT ID: NCT06299163 (https://classic.clinicaltrials.gov/show/NCT06299163)
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
NCT ID: NCT05032040 (https://classic.clinicaltrials.gov/show/NCT05032040)
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
NCT ID: NCT04703920 (https://classic.clinicaltrials.gov/show/NCT04703920)
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
NCT ID: NCT04282044 (https://classic.clinicaltrials.gov/show/NCT04282044)
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
NCT ID: NCT05523440 (https://classic.clinicaltrials.gov/show/NCT05523440)
ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors
NCT ID: NCT06161493 (https://classic.clinicaltrials.gov/show/NCT06161493)
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
NCT ID: NCT05922930 (https://classic.clinicaltrials.gov/show/NCT05922930)
Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer
NCT ID: NCT04502602 (https://classic.clinicaltrials.gov/show/NCT04502602)
Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery
NCT ID: NCT02884648 (https://classic.clinicaltrials.gov/show/NCT02884648)
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
NCT ID: NCT05453825 (https://classic.clinicaltrials.gov/show/NCT05453825)
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
NCT ID: NCT04918186 (https://classic.clinicaltrials.gov/show/NCT04918186)
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT ID: NCT01174121 (https://classic.clinicaltrials.gov/show/NCT01174121)
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer
NCT ID: NCT03462342 (https://classic.clinicaltrials.gov/show/NCT03462342)
PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
NCT ID: NCT05465941 (https://classic.clinicaltrials.gov/show/NCT05465941)
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT ID: NCT05489211 (https://classic.clinicaltrials.gov/show/NCT05489211)
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
NCT ID: NCT04840589 (https://classic.clinicaltrials.gov/show/NCT04840589)
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
NCT ID: NCT05601752 (https://classic.clinicaltrials.gov/show/NCT05601752)
Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy
NCT ID: NCT04415944 (https://classic.clinicaltrials.gov/show/NCT04415944)
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
NCT ID: NCT05870748 (https://classic.clinicaltrials.gov/show/NCT05870748)
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT ID: NCT04606914 (https://classic.clinicaltrials.gov/show/NCT04606914)
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
NCT ID: NCT04055649 (https://classic.clinicaltrials.gov/show/NCT04055649)
Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors
NCT ID: NCT05700669 (https://classic.clinicaltrials.gov/show/NCT05700669)
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
NCT ID: NCT06253520 (https://classic.clinicaltrials.gov/show/NCT06253520)
A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
NCT ID: NCT06051695 (https://classic.clinicaltrials.gov/show/NCT06051695)
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
NCT ID: NCT05733000 (https://classic.clinicaltrials.gov/show/NCT05733000)
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
NCT ID: NCT05746897 (https://classic.clinicaltrials.gov/show/NCT05746897)
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
NCT ID: NCT05415709 (https://classic.clinicaltrials.gov/show/NCT05415709)
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
NCT ID: NCT05585034 (https://classic.clinicaltrials.gov/show/NCT05585034)
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
NCT ID: NCT05446298 (https://classic.clinicaltrials.gov/show/NCT05446298)
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
NCT ID: NCT04092270 (https://classic.clinicaltrials.gov/show/NCT04092270)
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT ID: NCT04550494 (https://classic.clinicaltrials.gov/show/NCT04550494)
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
NCT ID: NCT05296512 (https://classic.clinicaltrials.gov/show/NCT05296512)
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
NCT ID: NCT05259696 (https://classic.clinicaltrials.gov/show/NCT05259696)
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
NCT ID: NCT05293496 (https://classic.clinicaltrials.gov/show/NCT05293496)
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
NCT ID: NCT03412877 (https://classic.clinicaltrials.gov/show/NCT03412877)
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
NCT ID: NCT04847063 (https://classic.clinicaltrials.gov/show/NCT04847063)
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
NCT ID: NCT05887609 (https://classic.clinicaltrials.gov/show/NCT05887609)
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT ID: NCT05739981 (https://classic.clinicaltrials.gov/show/NCT05739981)
A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
NCT ID: NCT05198804 (https://classic.clinicaltrials.gov/show/NCT05198804)
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients
NCT ID: NCT04213794 (https://classic.clinicaltrials.gov/show/NCT04213794)
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT ID: NCT04095364 (https://classic.clinicaltrials.gov/show/NCT04095364)
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
NCT ID: NCT06072781 (https://classic.clinicaltrials.gov/show/NCT06072781)
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
NCT ID: NCT05659381 (https://classic.clinicaltrials.gov/show/NCT05659381)
A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018
NCT ID: NCT04590326 (https://classic.clinicaltrials.gov/show/NCT04590326)
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
NCT ID: NCT03968406 (https://classic.clinicaltrials.gov/show/NCT03968406)
Study of DF6215 in Patients With Advanced Solid Tumors
NCT ID: NCT06108479 (https://classic.clinicaltrials.gov/show/NCT06108479)
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
NCT ID: NCT05239143 (https://classic.clinicaltrials.gov/show/NCT05239143)
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
NCT ID: NCT05864144 (https://classic.clinicaltrials.gov/show/NCT05864144)
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
NCT ID: NCT03872947 (https://classic.clinicaltrials.gov/show/NCT03872947)
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
NCT ID: NCT05200364 (https://classic.clinicaltrials.gov/show/NCT05200364)
Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies
NCT ID: NCT06052852 (https://classic.clinicaltrials.gov/show/NCT06052852)
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
NCT ID: NCT05548296 (https://classic.clinicaltrials.gov/show/NCT05548296)
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT ID: NCT05768139 (https://classic.clinicaltrials.gov/show/NCT05768139)
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
NCT ID: NCT05000294 (https://classic.clinicaltrials.gov/show/NCT05000294)
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
NCT ID: NCT05417594 (https://classic.clinicaltrials.gov/show/NCT05417594)
A Study of ZN-c3 in Patients With Platinum-Resistant Ovarian Cancer
NCT ID: NCT04516447 (https://classic.clinicaltrials.gov/show/NCT04516447)
A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
NCT ID: NCT06394804 (https://classic.clinicaltrials.gov/show/NCT06394804)
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
NCT ID: NCT05554328 (https://classic.clinicaltrials.gov/show/NCT05554328)
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
NCT ID: NCT06285097 (https://classic.clinicaltrials.gov/show/NCT06285097)
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
NCT ID: NCT06188520 (https://classic.clinicaltrials.gov/show/NCT06188520)
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
NCT ID: NCT05276973 (https://classic.clinicaltrials.gov/show/NCT05276973)
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT ID: NCT04180371 (https://classic.clinicaltrials.gov/show/NCT04180371)
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
NCT ID: NCT05185947 (https://classic.clinicaltrials.gov/show/NCT05185947)
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
NCT ID: NCT04469764 (https://classic.clinicaltrials.gov/show/NCT04469764)
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
NCT ID: NCT04329494 (https://classic.clinicaltrials.gov/show/NCT04329494)
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
NCT ID: NCT05554367 (https://classic.clinicaltrials.gov/show/NCT05554367)
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
NCT ID: NCT05007106 (https://classic.clinicaltrials.gov/show/NCT05007106)
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
NCT ID: NCT04044859 (https://classic.clinicaltrials.gov/show/NCT04044859)
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection
NCT ID: NCT03746431 (https://classic.clinicaltrials.gov/show/NCT03746431)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT ID: NCT05564377 (https://classic.clinicaltrials.gov/show/NCT05564377)
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
NCT ID: NCT05973487 (https://classic.clinicaltrials.gov/show/NCT05973487)
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
NCT ID: NCT05572684 (https://classic.clinicaltrials.gov/show/NCT05572684)
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
NCT ID: NCT04561362 (https://classic.clinicaltrials.gov/show/NCT04561362)
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)
NCT ID: NCT05445778 (https://classic.clinicaltrials.gov/show/NCT05445778)
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NCT ID: NCT05252390 (https://classic.clinicaltrials.gov/show/NCT05252390)
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT ID: NCT05277051 (https://classic.clinicaltrials.gov/show/NCT05277051)
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
NCT ID: NCT06065059 (https://classic.clinicaltrials.gov/show/NCT06065059)
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
NCT ID: NCT05691504 (https://classic.clinicaltrials.gov/show/NCT05691504)
A Study of SGN-PDL1V in Advanced Solid Tumors
NCT ID: NCT05208762 (https://classic.clinicaltrials.gov/show/NCT05208762)
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
NCT ID: NCT05112601 (https://classic.clinicaltrials.gov/show/NCT05112601)
PF-07104091 as a Single Agent and in Combination Therapy
NCT ID: NCT04553133 (https://classic.clinicaltrials.gov/show/NCT04553133)
A Study of SGN-B6A in Advanced Solid Tumors
NCT ID: NCT04389632 (https://classic.clinicaltrials.gov/show/NCT04389632)
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
NCT ID: NCT04925284 (https://classic.clinicaltrials.gov/show/NCT04925284)
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
NCT ID: NCT04429542 (https://classic.clinicaltrials.gov/show/NCT04429542)
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT ID: NCT06257264 (https://classic.clinicaltrials.gov/show/NCT06257264)
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
NCT ID: NCT05075993 (https://classic.clinicaltrials.gov/show/NCT05075993)
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
NCT ID: NCT05708950 (https://classic.clinicaltrials.gov/show/NCT05708950)
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
NCT ID: NCT04851119 (https://classic.clinicaltrials.gov/show/NCT04851119)
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT ID: NCT05613088 (https://classic.clinicaltrials.gov/show/NCT05613088)
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or Chemotherapy or TransCon TLR7/8 Agonist in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
NCT ID: NCT05081609 (https://classic.clinicaltrials.gov/show/NCT05081609)
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT ID: NCT02632448 (https://classic.clinicaltrials.gov/show/NCT02632448)
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
NCT ID: NCT04354246 (https://classic.clinicaltrials.gov/show/NCT04354246)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT ID: NCT04585750 (https://classic.clinicaltrials.gov/show/NCT04585750)
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NCT ID: NCT05215574 (https://classic.clinicaltrials.gov/show/NCT05215574)
Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NCT ID: NCT04913337 (https://classic.clinicaltrials.gov/show/NCT04913337)
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
NCT ID: NCT04140526 (https://classic.clinicaltrials.gov/show/NCT04140526)
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
NCT ID: NCT03686124 (https://classic.clinicaltrials.gov/show/NCT03686124)
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients With Advanced Solid Tumors
NCT ID: NCT05932862 (https://classic.clinicaltrials.gov/show/NCT05932862)
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT ID: NCT04657068 (https://classic.clinicaltrials.gov/show/NCT04657068)
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT ID: NCT03067181 (https://classic.clinicaltrials.gov/show/NCT03067181)
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
NCT ID: NCT05544929 (https://classic.clinicaltrials.gov/show/NCT05544929)
A Study of NX-1607 in Adults With Advanced Malignancies
NCT ID: NCT05107674 (https://classic.clinicaltrials.gov/show/NCT05107674)
A Beta-only IL-2 ImmunoTherapY Study
NCT ID: NCT05086692 (https://classic.clinicaltrials.gov/show/NCT05086692)
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
NCT ID: NCT05950464 (https://classic.clinicaltrials.gov/show/NCT05950464)
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
NCT ID: NCT04895709 (https://classic.clinicaltrials.gov/show/NCT04895709)
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications
NCT ID: NCT05827614 (https://classic.clinicaltrials.gov/show/NCT05827614)
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
NCT ID: NCT05538897 (https://classic.clinicaltrials.gov/show/NCT05538897)
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
NCT ID: NCT04956640 (https://classic.clinicaltrials.gov/show/NCT04956640)
A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors
NCT ID: NCT05672459 (https://classic.clinicaltrials.gov/show/NCT05672459)
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
NCT ID: NCT02611024 (https://classic.clinicaltrials.gov/show/NCT02611024)
(VELA) Study of BLU-222 in Advanced Solid Tumors
NCT ID: NCT05252416 (https://classic.clinicaltrials.gov/show/NCT05252416)
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
NCT ID: NCT05891171 (https://classic.clinicaltrials.gov/show/NCT05891171)
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT ID: NCT05325866 (https://classic.clinicaltrials.gov/show/NCT05325866)
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
NCT ID: NCT04196257 (https://classic.clinicaltrials.gov/show/NCT04196257)
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
NCT ID: NCT05500508 (https://classic.clinicaltrials.gov/show/NCT05500508)
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
NCT ID: NCT04319757 (https://classic.clinicaltrials.gov/show/NCT04319757)
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT ID: NCT04300556 (https://classic.clinicaltrials.gov/show/NCT04300556)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.